JP2022549335A - 新規方法 - Google Patents

新規方法 Download PDF

Info

Publication number
JP2022549335A
JP2022549335A JP2022519061A JP2022519061A JP2022549335A JP 2022549335 A JP2022549335 A JP 2022549335A JP 2022519061 A JP2022519061 A JP 2022519061A JP 2022519061 A JP2022519061 A JP 2022519061A JP 2022549335 A JP2022549335 A JP 2022549335A
Authority
JP
Japan
Prior art keywords
compound
formula
alkyl
psychosis
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022519061A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022549335A5 (enExample
Inventor
イー デイビス，ロバート
スナイダー，グレッチェン
リ，ポン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of JP2022549335A publication Critical patent/JP2022549335A/ja
Publication of JP2022549335A5 publication Critical patent/JP2022549335A5/ja
Priority to JP2025182550A priority Critical patent/JP7821366B1/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2022519061A 2019-09-25 2020-09-25 新規方法 Withdrawn JP2022549335A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025182550A JP7821366B1 (ja) 2019-09-25 2025-10-29 新規方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962906042P 2019-09-25 2019-09-25
US62/906,042 2019-09-25
PCT/US2020/052923 WO2021062307A1 (en) 2019-09-25 2020-09-25 Novel methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025182550A Division JP7821366B1 (ja) 2019-09-25 2025-10-29 新規方法

Publications (2)

Publication Number Publication Date
JP2022549335A true JP2022549335A (ja) 2022-11-24
JP2022549335A5 JP2022549335A5 (enExample) 2023-10-02

Family

ID=75166462

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022519061A Withdrawn JP2022549335A (ja) 2019-09-25 2020-09-25 新規方法
JP2025182550A Active JP7821366B1 (ja) 2019-09-25 2025-10-29 新規方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025182550A Active JP7821366B1 (ja) 2019-09-25 2025-10-29 新規方法

Country Status (4)

Country Link
US (2) US12478623B2 (enExample)
EP (1) EP4034119A4 (enExample)
JP (2) JP2022549335A (enExample)
WO (1) WO2021062307A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102967223B1 (ko) * 2013-12-03 2026-05-19 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
WO2019067591A1 (en) 2017-09-26 2019-04-04 Intra-Cellular Therapies, Inc. NEW SALTS AND CRYSTALS
US11408880B2 (en) 2018-05-17 2022-08-09 Northeastern University Lipid-free anchoring of thermophilic bacteriophage G20c portal adapter into solid-state nanopores
WO2020047408A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
EP4134101A1 (en) 2019-07-07 2023-02-15 Intra-Cellular Therapies, Inc. Deuterated lumateperone for the treatment of the bipolar ii disorder
WO2021119334A1 (en) 2019-12-11 2021-06-17 Intra-Cellular Therapies, Inc. Organic compound
IL300886A (en) * 2020-09-04 2023-04-01 Intra Cellular Therapies Inc New salts, crystals and co-crystals
WO2025111568A1 (en) * 2023-11-22 2025-05-30 Intra-Cellular Therapies, Inc. Lumateperone and analogues, as 5-ht2a or 5-ht2a/d2 receptor modulators, for use in the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and of psychiatric symptoms thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070037815A1 (en) * 2005-07-29 2007-02-15 Roger Tung Novel pharmaceutical compounds
WO2019178484A1 (en) * 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Novel methods

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU208484B (en) 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
WO2000077001A1 (en) 1999-06-15 2000-12-21 Du Pont Pharmaceuticals Company Substituted heterocycle fused gamma-carbolines
US7071186B2 (en) 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
RU2003121304A (ru) 2000-12-20 2005-01-27 Бристол-Маерс Сквибб Компани (Us) Замещенные пиридоиндолы в качестве агонистов и антагонистов серотонина
US6849619B2 (en) 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
US20050058703A1 (en) 2003-08-01 2005-03-17 Chang Robert C. Gelatin capsules
RU2401257C2 (ru) 2004-12-07 2010-10-10 Янссен Фармацевтика Н.В. Новые замещенные тетрациклические производные тетрагидрофурана, пирролидина и тетрагидротиофена
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
MX394214B (es) 2007-03-12 2025-03-24 Intra Cellular Therapies Inc Sintesis de gamma-carbolinas fusionadas con heterociclo substituido.
CN101983058A (zh) 2008-02-05 2011-03-02 克莱拉有限公司 缓解抑郁症或改善认知的组合物和方法
ES2530090T3 (es) 2008-03-12 2015-02-26 Intra-Cellular Therapies, Inc. Sólido de gamma-carbolinas fusionadas con heterociclo sustituido
CA2725342C (en) 2008-05-27 2024-02-20 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines for sleep disorders and other disorders
US8993572B2 (en) 2010-04-22 2015-03-31 Intra-Cellular Therapies, Inc. Pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines derivatives and [1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole derivatives
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US9428506B2 (en) 2012-04-14 2016-08-30 Intra-Cellular Therapies, Inc. Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders
BR112015005743A2 (pt) 2012-09-14 2017-07-04 Abbvie Deutschland derivados tricíclicos de quinoxalina e quinolina
WO2014145192A1 (en) 2013-03-15 2014-09-18 Intra-Cellular Therapies, Inc. Organic compounds
DK3043777T3 (da) 2013-09-10 2020-07-20 Fresh Cut Dev Llc Sublingual buprenorphinspray
KR102967223B1 (ko) 2013-12-03 2026-05-19 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
US9745300B2 (en) 2014-04-04 2017-08-29 Intra-Cellular Therapies, Inc. Organic compounds
KR20220054908A (ko) 2014-04-04 2022-05-03 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
US11123311B2 (en) 2016-01-05 2021-09-21 The Regents Of The University Of California Methods of treating mental disorders
RU2743513C2 (ru) * 2016-01-26 2021-02-19 Интра-Селлулар Терапиз, Инк. Органические соединения
IL281050B2 (en) 2016-03-25 2023-04-01 Intra Cellular Therapies Inc A controlled or delayed release pharmaceutical preparation containing a deuterated compound
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
WO2017172811A1 (en) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel co-crystals
WO2017172784A1 (en) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel salts and crystals
HUE057055T2 (hu) 2016-08-09 2022-04-28 Teva Pharmaceuticals Int Gmbh Lumateperon-ditozilátsó szilárd halmazállapotú formái
JP7013454B2 (ja) 2016-10-12 2022-02-15 イントラ－セルラー・セラピーズ・インコーポレイテッド アモルファス固体分散体
EP3600325A4 (en) 2017-03-24 2021-01-06 Intra-Cellular Therapies, Inc. UNIQUE COMPOSITIONS AND PROCESSES
WO2018189646A1 (en) 2017-04-10 2018-10-18 Dr. Reddy's Laboratories Limited AMORPHOUS FORM AND SOLID DISPERSIONS OF LUMATEPERONE p-TOSYLATE
JP7224333B2 (ja) 2017-07-26 2023-02-17 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
WO2019023062A1 (en) 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
WO2019067591A1 (en) 2017-09-26 2019-04-04 Intra-Cellular Therapies, Inc. NEW SALTS AND CRYSTALS
CN109867674A (zh) 2017-12-05 2019-06-11 上海度德医药科技有限公司 一种取代的杂环稠合γ-咔啉的新盐及其制备方法和晶型
SMT202600133T1 (it) 2018-03-23 2026-05-12 Intra Cellular Therapies Inc Composti organici
BR112020024885A2 (pt) 2018-06-06 2021-03-09 Intra-Cellular Therapies, Inc. Novos sais e cristais
US12144808B2 (en) 2018-08-29 2024-11-19 Intra-Cellular Therapies, Inc. Compositions and methods
AU2019328528B2 (en) * 2018-08-31 2025-01-23 Intra-Cellular Therapies, Inc. Novel methods
WO2020047408A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
WO2020112941A2 (en) 2018-11-27 2020-06-04 Teva Czech Industries S.R.O Solid state forms of lumateperone salts and processes for preparation of lumateperone and salts thereof
WO2020182978A1 (en) 2019-03-13 2020-09-17 Sandoz Ag Crystalline salt of a 5-ht2a receptor antagonist
EP4134101A1 (en) 2019-07-07 2023-02-15 Intra-Cellular Therapies, Inc. Deuterated lumateperone for the treatment of the bipolar ii disorder
WO2021119334A1 (en) 2019-12-11 2021-06-17 Intra-Cellular Therapies, Inc. Organic compound
LT4076461T (lt) 2019-12-19 2026-06-25 Intra-Cellular Therapies, Inc. Lumateperonas, skirtas panaudoti šizofrenijos gydymui
US20250195510A1 (en) 2022-05-18 2025-06-19 Intra-Cellular Therapies, Inc. Novel methods
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070037815A1 (en) * 2005-07-29 2007-02-15 Roger Tung Novel pharmaceutical compounds
WO2019178484A1 (en) * 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Novel methods

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"ITl-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes", EXPERT REVIEW OF NEUROTHERAPEUTICS, vol. 16, no. 6, JPN6024035449, 2016, pages 601 - 614, ISSN: 0005557723 *
"Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacolo", CNS SPECTRUMS, MBL COMMUNICATIONS, vol. 24, no. 1, JPN6024035451, August 2019 (2019-08-01), pages 38 - 69, ISSN: 0005557722 *
"Rapid Improvement of Acute Schizophrenia Symptoms After Intravenous Sodium Nitroprusside : A Randomi", JAMA PSYCHIATRY, vol. 70, no. 7, JPN6024035448, 2013, pages 668, ISSN: 0005557724 *

Also Published As

Publication number Publication date
JP2026047365A (ja) 2026-03-13
EP4034119A4 (en) 2023-10-18
EP4034119A1 (en) 2022-08-03
US20220362241A1 (en) 2022-11-17
WO2021062307A1 (en) 2021-04-01
JP7821366B1 (ja) 2026-03-05
US20260115188A1 (en) 2026-04-30
US12478623B2 (en) 2025-11-25

Similar Documents

Publication Publication Date Title
JP7821366B1 (ja) 新規方法
US12409176B2 (en) Methods of treating acute depression
AU2021290277B2 (en) Novel methods
JP7673040B2 (ja) 新規方法
KR102684468B1 (ko) 유기 화합물
JP2021519271A (ja) 有機化合物
JP2020079231A (ja) 有機化合物
CA3102948A1 (en) Novel methods
HK40087977A (en) Deuterated lumateperone for the treatment of the bipolar ii disorder

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230922

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250625

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250930

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20251204